Invesco Advisers, Inc.
Known title: DirectorCIK: 0000020430
Associated companies
Transaction History
| IVZ | ▲ Buy | Grant | 16,176 | $461K | 10/1/2026 | View on chart |
| IVZ | ▼ Sell | Other | 8,969 | $256K | 9/30/2026 | View on chart |
| IVZ | ▲ Buy | Grant | 15,149 | $431K | 9/1/2026 | View on chart |
| IVZ | ▼ Sell | Other | 8,969 | $255K | 8/31/2026 | View on chart |
| IVZ | ▼ Sell | Other | 52,637 | $1.4M | 8/31/2026 | View on chart |
| IVZ | ▲ Buy | Grant | 13,519 | $384K | 8/3/2026 | View on chart |
| IVZ | ▲ Buy | Grant | 99,706 | $2.6M | 8/3/2026 | View on chart |
| IVZ | ▼ Sell | Other | 8,969 | $254K | 7/31/2026 | View on chart |
| IVZ | ▲ Buy | Grant | 13,812 | $391K | 7/1/2026 | View on chart |
| IVZ | ▼ Sell | Other | 5,779 | $164K | 6/29/2026 | View on chart |
| IVZ | ▲ Buy | Grant | 13,217 | $373K | 6/1/2026 | View on chart |
| IVZ | ▼ Sell | Other | 5,779 | $163K | 5/29/2026 | View on chart |
| IVZ | ▼ Sell | Other | 41,491 | $1.1M | 5/29/2026 | View on chart |
| IVZ | ▲ Buy | Grant | 85,861 | $2.2M | 5/1/2026 | View on chart |
| IVZ | ▲ Buy | Grant | 13,479 | $381K | 5/1/2026 | View on chart |
| IVZ | ▼ Sell | Other | 5,779 | $163K | 4/30/2026 | View on chart |
| IVZ | ▲ Buy | Grant | 11,257 | $317K | 4/1/2026 | View on chart |
| IVZ | ▼ Sell | Other | 5,779 | $163K | 3/31/2026 | View on chart |
| IVZ | ▲ Buy | Grant | 11,925 | $335K | 3/1/2026 | View on chart |
| IVZ | ▼ Sell | Other | 110,485 | $2.8M | 2/27/2026 | View on chart |
| IVZ | ▼ Sell | Other | 5,779 | $162K | 2/27/2026 | View on chart |
| IVZ | ▲ Buy | Grant | 264,024 | $6.8M | 2/2/2026 | View on chart |
| IVZ | ▲ Buy | Grant | 11,508 | $324K | 2/1/2026 | View on chart |
| IVZ | ▼ Sell | Other | 5,779 | $163K | 1/30/2026 | View on chart |
| IVZ | ▲ Buy | Grant | 10,761 | $302K | 1/2/2026 | View on chart |
| IVZ | ▼ Sell | Other | 5,779 | $162K | 12/31/2025 | View on chart |
| IVZ | ▲ Buy | Grant | 10,863 | $304K | 12/1/2025 | View on chart |
| IVZ | ▼ Sell | Other | 5,779 | $161K | 11/28/2025 | View on chart |
| IVZ | ▼ Sell | Other | 18,003 | $463K | 11/28/2025 | View on chart |
| IVZ | ▲ Buy | Grant | 65,555 | $1.7M | 11/3/2025 | View on chart |
| IVZ | ▲ Buy | Grant | 9,574 | $268K | 11/1/2025 | View on chart |
| IVZ | ▼ Sell | Other | 5,779 | $161K | 10/31/2025 | View on chart |
| IVZ | ▲ Buy | Grant | 9,304 | $260K | 10/1/2025 | View on chart |
| IVZ | ▼ Sell | Other | 5,779 | $162K | 9/30/2025 | View on chart |
| IVZ | ▲ Buy | Grant | 8,878 | $248K | 9/1/2025 | View on chart |
| IVZ | ▼ Sell | Other | 12,142 | $311K | 8/29/2025 | View on chart |
| IVZ | ▼ Sell | Other | 5,778 | $161K | 8/29/2025 | View on chart |
| IVZ | ▲ Buy | Grant | 52,636 | $1.3M | 8/1/2025 | View on chart |
| IVZ | ▲ Buy | Grant | 8,409 | $235K | 8/1/2025 | View on chart |
| IVZ | ▼ Sell | Other | 5,778 | $161K | 7/31/2025 | View on chart |
| IVZ | ▲ Buy | Grant | 8,620 | $241K | 7/1/2025 | View on chart |
| IVZ | ▼ Sell | Other | 4,617 | $129K | 6/30/2025 | View on chart |
| IVZ | ▲ Buy | Grant | 8,310 | $232K | 6/1/2025 | View on chart |
| IVZ | ▼ Sell | Other | 4,618 | $129K | 5/30/2025 | View on chart |
| IVZ | ▼ Sell | Other | 5,792 | $148K | 5/30/2025 | View on chart |
| IVZ | ▲ Buy | Grant | 7,797 | $220K | 5/1/2025 | View on chart |
| IVZ | ▲ Buy | Grant | 41,491 | $1.1M | 5/1/2025 | View on chart |
| IVZ | ▼ Sell | Other | 4,618 | $130K | 4/30/2025 | View on chart |
| IVZ | ▲ Buy | Grant | 6,792 | $192K | 4/1/2025 | View on chart |
| IVZ | ▼ Sell | Other | 4,618 | $130K | 3/31/2025 | View on chart |
| IVZ | ▲ Buy | Grant | 6,811 | $193K | 3/1/2025 | View on chart |
| IVZ | ▼ Sell | Other | 4,618 | $131K | 2/28/2025 | View on chart |
| IVZ | ▼ Sell | Other | 81,185 | $2.1M | 2/3/2025 | View on chart |
| IVZ | ▲ Buy | Grant | 29,300 | $746K | 2/3/2025 | View on chart |
| IVZ | ▲ Buy | Grant | 6,586 | $187K | 2/1/2025 | View on chart |
| IVZ | ▼ Sell | Other | 4,618 | $131K | 1/31/2025 | View on chart |
| IVZ | ▲ Buy | Grant | 6,050 | $172K | 1/1/2025 | View on chart |
| IVZ | ▼ Sell | Other | 4,618 | $131K | 12/31/2024 | View on chart |
| IVZ | ▲ Buy | Grant | 6,178 | $177K | 12/1/2024 | View on chart |
| IVZ | ▼ Sell | Other | 4,618 | $132K | 11/29/2024 | View on chart |
| IVZ | ▲ Buy | Grant | 18,003 | $456K | 11/1/2024 | View on chart |
| IVZ | ▲ Buy | Grant | 5,826 | $168K | 11/1/2024 | View on chart |
| IVZ | ▼ Sell | Other | 4,618 | $133K | 10/31/2024 | View on chart |
| IVZ | ▲ Buy | Grant | 6,032 | $175K | 10/1/2024 | View on chart |
| IVZ | ▼ Sell | Other | 4,618 | $134K | 9/30/2024 | View on chart |
| IVZ | ▲ Buy | Grant | 5,924 | $173K | 9/1/2024 | View on chart |
| IVZ | ▼ Sell | Other | 4,618 | $135K | 8/30/2024 | View on chart |
| IVZ | ▲ Buy | Grant | 12,142 | $306K | 8/1/2024 | View on chart |
| IVZ | ▲ Buy | Grant | 5,659 | $165K | 8/1/2024 | View on chart |
| IVZ | ▼ Sell | Other | 4,618 | $135K | 7/31/2024 | View on chart |
| IVZ | ▲ Buy | Grant | 5,758 | $169K | 7/1/2024 | View on chart |
| IVZ | ▼ Sell | Other | 2,820 | $83K | 6/28/2024 | View on chart |
| IVZ | ▲ Buy | Grant | 5,573 | $164K | 6/1/2024 | View on chart |
| IVZ | ▼ Sell | Other | 2,820 | $83K | 5/31/2024 | View on chart |
| IVZ | ▲ Buy | Grant | 5,792 | $145K | 5/1/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
Invesco to Report Q3 2026 Results; Dividends Declared
Invesco has announced it will release its third-quarter 2026 financial results soon. The company also declared dividends for its closed-end funds, a move that may appeal to income-focused investors given the stock's 5.79% dividend yield. Recent news coverage has focused on the firm's various ETFs and mutual funds, highlighting its broad product lineup.
Invesco to Report Q3 2026 Results; Dividends Declared. Invesco has announced it will release its third-quarter 2026 financial results soon. The company also declared dividends for its closed-end funds, a move that may appeal to income-focused investors given the stock's 5.79% dividend yield. Recent news coverage has focused on the firm's various ETFs and mutual funds, highlighting its broad product lineup.